Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
INSILICO Reaches $900M+ Drug Development Collaboration with Qilu Pharmaceutical
Recommend 1 Positive 4 Negative 0 |
||||
|
||||
|
INSILICO (03696.HK) and Qilu Pharmaceutical Group, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, entered into a strategic partnership on innovative drug development, and signed the relevant agreement, as announced by INSILICO. The two parties aim to leverage INSILICO's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management. Pursuant to the agreement, INSILICO will utilize its proprietary Pharma.AI platform to focus on the design and optimization of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization procedures. The total contract value of the agreement exceeds $931 million, including development and commercialization milestone payments, as well as single-digit royalties based on net sales. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
